U.S. Patent 7,682,628: Scope, Claim Construction, Patent Landscape, and Generic Entry Risk for Zolpidem

U.S. Patent 7,682,628 protects a method of treating insomnia with a rapidly dissolving, buffered zolpidem solid dosage form that raises salivary pH to at least about 7.8 and delivers zolpidem through the oral mucosa. The patent does not broadly cover all zolpidem products, all sublingual tablets, or the zolpidem molecule itself. Its commercial scope depends on the combination of formulation performance, salivary pH, oral-mucosal absorption, dissolution speed, and, for certain dependent claims, dose and buffer composition. [1]

The principal infringement risk is concentrated in fast-dissolving sublingual or buccal zolpidem products using an alkalinizing buffer. Conventional swallowed tablets, oral sprays, products that do not raise saliva to the claimed pH, and formulations that fail the dissolution or transmucosal-absorption limitations have stronger design-around positions.

What does U.S. Patent 7,682,628 protect?

The patent protects a treatment method, not a standalone composition.

Claim 1 requires the following elements:

Claim element	Scope
Patient	A subject prone to insomnia
Active ingredient	Zolpidem or a pharmaceutically acceptable salt
Dosage form	Solid pharmaceutical composition
Buffer	Present in the composition
Salivary effect	Raises saliva to about pH 7.8 or greater
Absorption route	Zolpidem crosses a permeable membrane of the oral mucosa
Dissolution	At least 75% dissolves within about 10 minutes or less in the oral cavity
Therapeutic use	Treatment of insomnia

Every limitation must be met for literal infringement. A product that satisfies the active-ingredient, dosage-form, and rapid-dissolution limitations but does not produce salivary pH of approximately 7.8 or higher would have a substantial noninfringement position under the literal language of claim 1.

The claim is narrower than a conventional product claim because it requires proof of what the formulation does in the patient’s oral cavity. It is also narrower than a general method-of-treatment claim because it specifies the delivery mechanism and performance characteristics.

How should claim 1 be construed?

Claim 1 combines formulation limitations with in vivo treatment limitations. The most important construction issues are pH, dissolution, absorption, and the meaning of “about.”

Salivary pH limitation

The buffer must raise saliva to “a pH of about 7.8 or greater.” This language creates two issues:

The relevant pH is saliva pH, not necessarily the pH of the tablet or dissolution medium.
“About 7.8” introduces a tolerance question that would depend on specification support, testing methodology, and claim construction.

A formulation with a tablet slurry pH of 8.0 does not automatically satisfy the limitation if it does not raise saliva to the claimed level. Conversely, a formulation may face risk if clinical or in-mouth testing shows salivary alkalinization at or above the construed threshold.

The claim does not require a particular buffer unless a dependent claim applies. Any buffer capable of producing the claimed salivary pH can potentially satisfy claim 1.

Dissolution limitation

Claim 1 requires that at least 75% of the solid composition dissolve within about 10 minutes or less in the oral cavity. The language is materially different from a standard in vitro dissolution specification because it refers to dissolution “within an oral cavity following administration.”

Key variables include:

Amount dissolved;
Time point;
Oral-cavity test conditions;
Saliva volume and composition;
Whether residue is swallowed;
Whether the test measures dissolution or disintegration;
Whether the claimed percentage is based on total zolpidem, total tablet mass, or another validated basis.

A product that disintegrates rapidly but leaves substantial undissolved material may not satisfy the claim. Claims 3 and 4 narrow the dissolution period to approximately one to three minutes and two to three minutes, respectively.

Oral-mucosal absorption limitation

The claim requires zolpidem to be absorbed across a permeable membrane of the oral mucosa. This limitation distinguishes the claimed method from a dosage form that merely dissolves in the mouth and is then swallowed for gastrointestinal absorption.

The specification and prosecution history would be important in determining whether the claim requires proof of a quantitatively significant transmucosal fraction or merely absorption occurring through the oral mucosa. A product designed for buccal or sublingual delivery presents greater risk than a rapidly dissolving product expressly intended for swallowing.

“Subject prone to insomnia”

This limitation is unlikely to create a major commercial barrier where the product is prescribed or marketed for insomnia. It does, however, require a treatment context involving a patient susceptible to insomnia rather than an entirely unrelated use.

How do claims 2 through 17 change the patent scope?

The dependent claims create narrower fallback positions. They do not expand claim 1.

Claim	Added limitation	Practical effect
2	Binder and disintegrating agent	Covers a conventional rapidly disintegrating excipient architecture
3	Dissolution within about 1-3 minutes	Narrower rapid-dissolution embodiment
4	Dissolution within about 2-3 minutes	Narrower than claim 3
5	Sublingual administration	Excludes non-sublingual routes from this dependent claim
6	Specified oral mucosa	Covers sublingual, buccal, gingival, palatal, and lip-lining mucosa
7	Mean peak plasma concentration of 20-100 ng/mL within about 30 minutes	Adds a pharmacokinetic limitation
8	Therapeutically effective amount enters bloodstream within about 30 minutes	Adds an onset and systemic-exposure limitation
9	Carbonate and bicarbonate buffer	Narrows buffer chemistry
10	Carbonate:bicarbonate ratio of about 1:1 to 1:10	Defines a broad ratio range
11	Lozenge	Narrows dosage form
12	Tablet	Narrows dosage form
13	Carbonate:bicarbonate ratio of about 1:1 to 1:5	Narrower than claim 10
14	Average plasma concentration of 20-300 ng/mL	Adds a broad concentration limitation
15	Zolpidem tartrate	Narrows the salt
16	Zolpidem amount of 1-5 mg	Covers low-dose products through 5 mg
17	Zolpidem amount of 2-5 mg	Narrower dose range

Claims 10 and 13 overlap. Claim 13 is narrower because every ratio from approximately 1:1 through 1:5 falls within claim 10’s 1:1 through 1:10 range.

Claims 3 and 4 also overlap. A product dissolving in approximately 2.5 minutes can potentially satisfy both, subject to the meaning of “about.”

Claim 16 does not exclude a 10-mg product from claim 1 because claim 1 has no dosage limitation. A 10-mg product would fall outside claims 16 and 17 but could still present risk under claim 1 or other dependent claims if all relevant limitations are met.

What formulations are protected by U.S. Patent 7,682,628?

The clearest protected formulation profile is:

Zolpidem tartrate or another pharmaceutically acceptable zolpidem salt;
A solid oral dosage form;
A carbonate and bicarbonate buffer;
A carbonate:bicarbonate ratio of approximately 1:1 to 1:10, or 1:1 to 1:5 under claim 13;
A binder and disintegrant;
Sublingual or buccal administration;
At least 75% dissolution within approximately 10 minutes;
Salivary pH of approximately 7.8 or greater;
Rapid systemic exposure through oral mucosa.

The claims do not require every one of these features. Carbonate and bicarbonate are required only by claims 9, 10, and 13. Binder and disintegrant are required only by claim 2. Sublingual administration is required only by claim 5, although claim 6 includes sublingual mucosa among the covered mucosal sites.

The patent therefore has two distinct protection layers:

A broad functional layer under claim 1, covering any qualifying buffer and any solid dosage form meeting the performance and absorption requirements.
Narrower formulation and dosage-form layers covering carbonate/bicarbonate systems, tablets, lozenges, binders, disintegrants, and specific doses.

How strong is the patent estate for fast-acting sublingual zolpidem?

The asserted claim set has moderate technical breadth but meaningful proof burdens.

Strengths

The claims combine several commercially relevant characteristics:

Rapid dissolution;
Alkalinization of saliva;
Oral-mucosal absorption;
Faster plasma exposure;
Low-dose zolpidem delivery;
Sublingual and buccal administration.

A competitor cannot avoid the patent merely by changing tablet shape, flavor, or excipient grade if the resulting product still meets the functional limitations.

The claims also cover multiple mucosal sites through claim 6. This reduces the value of switching from sublingual to buccal delivery where the product still uses the claimed oral-mucosal pathway.

Weaknesses

The claims contain limitations that may be difficult to prove consistently:

Salivary pH must reach the claimed threshold;
Dissolution must be measured in the oral cavity;
Oral-mucosal absorption must be demonstrated;
Claims 7, 8, and 14 require pharmacokinetic or exposure evidence;
“About” ranges may produce claim-construction disputes;
The claims are method claims and require an act of administration or inducement.

The patent is therefore less exposed to a conventional swallowed zolpidem tablet than to a product designed specifically for rapid sublingual or buccal absorption.

How can a generic or follow-on product design around the claims?

Potential design-around strategies include:

Design-around	Likely claim impact
Use a non-alkalinizing formulation	Avoids the pH limitation if saliva does not reach the claimed threshold
Maintain salivary pH below approximately 7.8	Directly targets claim 1
Use a conventional swallowed tablet	Challenges the oral-mucosal absorption limitation
Use an oral spray without a solid composition	May avoid the solid-dosage-form limitation
Use a dosage form that dissolves more slowly than the claimed period	Targets the dissolution limitation
Use a different delivery route, such as gastrointestinal delivery	Avoids oral-mucosal absorption
Use a non-zolpidem hypnotic	Avoids the active-ingredient limitation
Use a formulation with no carbonate/bicarbonate system	Avoids claims 9, 10, and 13, but not necessarily claim 1
Use a dose above 5 mg	Avoids claims 16 and 17, but not claim 1
Use a formulation with rapid dissolution but no demonstrated transmucosal absorption	May avoid the absorption limitation

A design-around must be tested against the full claim set. Avoiding carbonate and bicarbonate does not avoid claim 1, which does not specify buffer chemistry. Similarly, avoiding a 2-5 mg dose does not avoid claim 1 because the independent claim does not impose a dose range.

The doctrine of equivalents may limit the value of a purely formal change, particularly where a substitute buffer performs substantially the same pH-raising function in substantially the same way to obtain rapid transmucosal zolpidem absorption. The prosecution history would determine whether particular equivalents were surrendered.

What is the relationship between this patent and FDA-approved sublingual zolpidem?

FDA-approved sublingual zolpidem products include Edluar and Intermezzo, which use zolpidem tartrate in sublingual dosage forms. Edluar was approved in 2009 in 5-mg and 10-mg strengths. Intermezzo was approved in 2011 in lower-dose strengths for middle-of-the-night awakening. [2,3]

The regulatory product label does not by itself establish infringement. The following distinctions matter:

A 5-mg product may fall within claims 16 and 17 if the other limitations are met.
A 10-mg product is outside claims 16 and 17 but may still implicate claim 1.
FDA approval of a sublingual product does not prove that it raises saliva to pH 7.8 or higher.
FDA labeling and pharmacokinetic data may provide evidence relevant to claims 7, 8, and 14.
The product’s actual formulation and in-mouth performance are required for a complete claim chart.

FDA approval, Orange Book listing, and patent enforceability are separate issues. A patent may be listed in the Orange Book for an approved drug, but listing does not establish that every claim is valid or infringed. Conversely, a patent not listed in the Orange Book may still be relevant to non-ANDA litigation or commercial freedom-to-operate analysis. [4,5]

What is the Orange Book status and exclusivity position?

The Orange Book status of a patent is determined by FDA listing records for the relevant NDA, not by the patent claims alone. The relevant products are prescription zolpidem products approved under separate NDAs, and listing analysis must be performed at the NDA and strength level. [4]

FDA exclusivity and patent term should be separated:

Protection type	Function
New chemical entity exclusivity	Blocks certain ANDA submissions for the statutory period
Three-year exclusivity	Protects approved changes supported by new clinical investigations
Patent protection	Depends on valid, enforceable claims and statutory term
Pediatric exclusivity	Can add six months to qualifying patents or exclusivities
Orange Book listing	Identifies patents submitted for an approved drug

The claim set supplied does not establish the patent’s current term, patent-term adjustment, terminal disclaimer status, pediatric extension, Orange Book listing, or delisting history. Those issues are controlled by the USPTO patent file, FDA Orange Book records, and the applicable NDA records. [1,4]

When does U.S. Patent 7,682,628 lose exclusivity?

Patent expiration cannot be calculated reliably from the grant date alone. U.S. utility patents generally run for 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and other statutory rules. [6]

For this patent, the operative date must be determined from:

Earliest claimed priority date;
Nonprovisional filing date;
Patent-term adjustment;
Any terminal disclaimer;
Any patent-term extension;
Any pediatric exclusivity attached to an approved product.

After expiration, the claims cease to provide enforceable patent exclusivity, although regulatory exclusivity, contractual restrictions, trade secrets, and other patents may remain relevant.

Which companies are most exposed to the patent?

The principal exposure is for manufacturers of:

Sublingual zolpidem tablets;
Buccal zolpidem tablets;
Fast-dissolving zolpidem lozenges;
Low-dose zolpidem products intended for rapid onset;
Buffered zolpidem formulations;
Products that report rapid plasma exposure after oral administration.

Manufacturers of conventional swallowed zolpidem tablets face lower risk under this claim set because the claims require oral-mucosal absorption and rapid in-mouth dissolution. Manufacturers of non-zolpidem insomnia drugs do not fall within the literal active-ingredient limitation.

The commercial competitive set includes oral zolpidem products, non-zolpidem hypnotics, melatonin-receptor agonists, dual orexin receptor antagonists, and other rapid-onset sleep therapies. The patent is most relevant to competition within the sublingual zolpidem segment, not to the entire insomnia market.

What litigation, Paragraph IV, and settlement issues matter?

A Paragraph IV challenge would likely focus on one or more of the following:

Invalidity based on anticipation or obviousness over earlier sublingual or rapidly dissolving zolpidem formulations.
Lack of written description or enablement for the salivary-pH and in-mouth dissolution limitations.
Indefiniteness of “about 7.8,” “about 10 minutes,” and related pharmacokinetic ranges.
Noninfringement based on the absence of transmucosal absorption.
Failure to meet the claimed pH threshold under reproducible testing.
Absence of a carbonate/bicarbonate buffer for dependent claims.
Dose outside the ranges in claims 16 and 17.

An ANDA applicant would typically certify under Paragraph IV if it concluded that the listed patent was invalid, unenforceable, or not infringed. The patent owner could then bring an action under 35 U.S.C. §271(e)(2), potentially triggering the statutory stay applicable to the ANDA approval process. [7]

No settlement terms, launch dates, or litigation outcome are established by the claim language supplied. A settlement could permit an authorized generic, a licensed launch, a date-certain entry, or restrictions tied to formulation and indication. Those outcomes cannot be inferred from the claims.

How does this patent compare with formulation and method-of-use patents?

U.S. Patent 7,682,628 is primarily a method patent with embedded formulation-performance limitations.

Patent type	Typical protection	Relevance here
Active-ingredient patent	Zolpidem molecule or salt	Not the focus of these claims
Composition patent	Ingredients and physical dosage form	Claims 2, 9, 10, 11, 12, 13, 15-17 narrow the method around these features
Method-of-treatment patent	Administration of a product for insomnia	Core structure of claims 1-17
Method-of-use patent	Specific patient, timing, or indication	Claims 1, 7, 8, and 14 add treatment and PK limitations
Manufacturing patent	Process for making the dosage form	Not present in the supplied claims
Device or delivery patent	Applicator, dispenser, or delivery system	Not present in the supplied claims

The absence of manufacturing claims is commercially important. A manufacturer may avoid this patent while still facing separate patents covering tablet manufacture, taste masking, granulation, excipient combinations, packaging, or delivery devices.

What is the geographic coverage of the patent?

U.S. Patent 7,682,628 provides U.S. rights only. Parallel protection would require corresponding patents or applications in other jurisdictions, such as Europe, Canada, Japan, or Australia. Foreign family members may differ materially in:

Claim scope;
Expiration date;
Validity;
Prosecution amendments;
Patent-term adjustment or extension;
Litigation history;
Regulatory linkage.

A U.S. freedom-to-operate opinion cannot be extended automatically to foreign markets. The U.S. claims also do not protect manufacturing or sales occurring entirely outside the United States unless a separate jurisdictional basis applies.

Key Takeaways

U.S. Patent 7,682,628 is directed to rapid transmucosal zolpidem treatment for insomnia.
Claim 1 requires a solid zolpidem composition, a buffer that raises saliva to approximately pH 7.8 or higher, oral-mucosal absorption, and at least 75% dissolution within approximately 10 minutes.
Claims 9, 10, and 13 specifically target carbonate/bicarbonate buffering and defined ratios.
Claims 16 and 17 cover 1-5 mg and 2-5 mg zolpidem doses, respectively.
A 10-mg product avoids the dose limitations of claims 16 and 17 but may still implicate claim 1.
The strongest design-around routes involve eliminating the claimed salivary pH effect, avoiding oral-mucosal absorption, using a non-solid dosage form, or materially slowing dissolution.
FDA approval and Orange Book listing do not establish infringement or validity.
Patent expiration requires review of the USPTO term calculation, patent-term adjustment, terminal disclaimers, extensions, and applicable regulatory exclusivity.
The supplied claims do not include manufacturing-process protection.
The highest commercial risk is for buffered, fast-dissolving sublingual or buccal zolpidem products.

FAQs About U.S. Patent 7,682,628 and Zolpidem

Does U.S. Patent 7,682,628 cover ordinary Ambien tablets?

Not necessarily. Ordinary swallowed zolpidem tablets generally do not satisfy the claimed oral-mucosal absorption and rapid in-mouth dissolution limitations.

Does using zolpidem tartrate automatically infringe the patent?

No. Zolpidem tartrate is required only by claim 15. A product must also satisfy the underlying limitations of claim 1, including salivary alkalinization, oral-mucosal absorption, and rapid dissolution.

Can a non-carbonate buffer avoid the patent?

It may avoid claims 9, 10, and 13, but it does not automatically avoid claim 1. Claim 1 covers a buffer without specifying carbonate or bicarbonate.

Does a sublingual zolpidem product infringe automatically?

No. Sublingual administration increases relevance, but infringement still requires the other claim elements, including the pH, dissolution, and oral-mucosal absorption limitations.

Can a generic launch before patent expiration?

A generic applicant may pursue a Paragraph IV certification, a noninfringement position, a validity challenge, or a formulation design-around. Commercial launch timing depends on patent term, FDA exclusivity, litigation, settlement terms, and the final product’s claim coverage.

References

U.S. Patent No. 7,682,628. (2010). Methods and compositions for treating insomnia. United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2009). Edluar (zolpidem tartrate) sublingual tablets prescribing information. FDA.
U.S. Food and Drug Administration. (2011). Intermezzo (zolpidem tartrate) sublingual tablets prescribing information. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
U.S. Food and Drug Administration. (n.d.). Approved drug product patent and exclusivity information. FDA.
United States Code, 35 U.S.C. §§154, 155, 156.
United States Code, 35 U.S.C. §271(e)(2).

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2005215782	⤷ Start Trial
Brazil	PI0507733	⤷ Start Trial
Canada	2556450	⤷ Start Trial
Canada	2816904	⤷ Start Trial
China	100548281	⤷ Start Trial
China	1929822	⤷ Start Trial
European Patent Office	1715853	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 7,682,628

Summary for Patent: 7,682,628